Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.73 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.73 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13867477 | 1.00 | CARM1 (0.73) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL13867466 | 1.00 | CARM1 (0.73) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL23768688 | 0.98 | CARM1 (0.70) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL1268626 | 0.98 | CARM1 (0.70) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL2356698 | 0.98 | CARM1 (0.70) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7255511 | 0.95 | CARM1 (0.67) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL1663805 | 0.95 | — | — | |
| SCHEMBL4342747 | 0.93 | CARM1 (0.70) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL17519179 | 0.91 | CARM1 (0.61) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 | |
| SCHEMBL2687491 | 0.91 | CARM1 (0.67) | CARM1PRMT6PRMT8HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110812-B1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORP (US) | 2019-04-10 | — | — | EP | claimed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | claimed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1163212-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | EP | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| US-6794380-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; ANTIALLERGENS | ASTRAZENECA AB (SE) | 2004-09-21 | — | — | US | claimed |
| EP-1163237-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| EP-0495249-B1 | Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas | BAYER AG (DE) | 1994-07-27 | — | — | EP | claimed |
| US-5134217-A | Forming polyurethanes modified with chain extension agents for foams | BAYER AKTIENGESELLSCHAFT (DE) | 1992-07-28 | — | — | US | claimed |
| EP-0495249-A1 | Use of N-(aminoalkyl)-pyrrolidines as a catalyst for the polyisocyanate-poly-addition process, process for the preparation of polyurethane-ureas | BAYER AG (DE) | 1992-07-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | CARM1 1153/4885PRMT6 354/4885PRMT8 1211/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | CARM1 527/4885PRMT6 444/4885PRMT8 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.